STOCKHOLM, Sweden--(BUSINESS WIRE)--Medivir (STO:MVIRB): • License agreement signed with Bristol-Myers Squibb for MIV-170 with a total contract value of USD 104.5m. • MIV-606 outlicensed to a total contract value of USD 24,5 m and shares in Epiphany Biosciences. • Phase III study on Lipsovir® (ME-609) against labial herpes started in July, 25% of patients in the study treated in the third quarter. • Consolidated net sales in 1 January-30 September 2006 totaled SEK 88.1 (41.0) m, of which continuing operations represented SEK 31.8 (41.0) m and discontinued operations SEK 56.3 (0) m. • The loss after tax amounted to SEK -115.0 (-112.6) m; earnings per share were SEK -8.91 (-8.72).
